DWDavid White

David White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David White has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outpatient paracentesis for Ovarian Hyperstimulation Syndrome: STOP-OHSS feasibility study and RCT Synopsis

    by Mostafa Metwally, Katie Ridsdale, Clare Pye, Munya Dimairo, Amy Barr, Ying Cheong, Lauren Desoysa, Sarah Drabble, Andrew Drakeley, Isaac Evbuomwan, et al.

    Background: Ovarian hyperstimulation syndrome is a potentially serious complication of fertility treatments. Standard care often involves monitoring, then hospitalisation for severe cases. Some evidence suggests early outpatient paracentesis may prevent hospitalisation, but adequately powered randomised trials are lacking. Objectives: To establish the clinical and cost-effectiveness, safety and acceptability of early active outpatient management for moderate or severe ovarian hyperstimulation syndrome. Design and methods: A pragmatic, parallel, open-label, multicentre, superiority, adaptive, group sequential randomised controlled trial with an internal pilot was planned. The study included preliminary qualitative work and a post-trial survey. The main trial recruited participants with moderate or severe, early or late ovarian hyperstimulation syndrome from UK fertility clinics. Participants were randomised 1 : 1 to receive either outpatient paracentesis or usual care (conservative management). The primary outcome was ovarian hyperstimulation syndrome-related hospital admission within 28 days. Results: The trial was terminated early due to poor recruitment. Only 8 participants were randomised (5 to conservative management, 3 to outpatient paracentesis) across 3 of 9 opened sites, compared to the planned 224 participants. All eight had moderate ovarian hyperstimulation syndrome at baseline. Two participants were hospitalised for ovarian hyperstimulation syndrome-related reasons (one from each group). Six participants’ symptoms resolved during follow-up, while two had unknown outcomes. There were no reported serious adverse events caused by the intervention. The post-trial survey of 16 fertility centres found increased use of preventive measures like freeze-all cycles, antagonist protocols and gonadotropin-releasing hormone trigger, during and after the SARS-CoV-2 (COVID-19) pandemic. Limitations: The small sample size precludes drawing any definitive conclusions about effectiveness, safety or cost-effectiveness. The study was severely impacted by the COVID-19 pandemic, affecting site set-up and recruitment, and changes in clinical practice during the pandemic may have reduced ovarian hyperstimulation syndrome cases. Conclusions: No definitive clinical conclusions can be drawn from this study about the effectiveness of outpatient management compared to conservative management. The pandemic prompted lasting modifications in ovarian hyperstimulation syndrome prevention strategies at many fertility clinics. Future work: Given the observed low incidence rates of ovarian hyperstimulation syndrome and challenges in recruitment, future research may need to consider alternative study designs in observational settings rather than randomised trials that reflect the changing reality of clinical management and prevention of ovarian hyperstimulation syndrome, particularly following the recent COVID pandemic. Additionally, the research community should reflect on strategies to improve trial resilience and adaptability in the face of major disruptions like pandemics. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128137.

  • Open Access

    Views on outpatient paracentesis and GnRH antagonists for ovarian hyperstimulation syndrome: a qualitative study of patients and healthcare professionals

    by Elizabeth Lumley, Alicia O’CAthain, Katie Ridsdale, Sarah Drabble, David White, Clare Pye, Jessica Wright, Andrew Drakeley, Ying Cheong, Raj Mathur, et al.

    Background: Ovarian hyperstimulation syndrome is a significant complication of fertility treatment, where the ovaries become enlarged if they are overstimulated, resulting in fluid leakage. Ovarian hyperstimulation syndrome can be classified as mild, moderate or severe. Symptoms vary dependent on severity but can include abdominal swelling, pain, nausea and vomiting, and shortness of breath. Treatment typically consists of monitoring initially, with active intervention if the condition progresses to a severe state, requiring hospitalisation. This study explored the acceptability and feasibility of outpatient paracentesis, and of gonadotropin-releasing hormone antagonists, as early interventions for ovarian hyperstimulation syndrome. Methods: We conducted qualitative semi-structured interviews with healthcare professionals from fertility clinics ( n = 8) and patients who had experienced ovarian hyperstimulation syndrome ( n = 10) across six United Kingdom fertility clinics. Interviews explored views on the proposed treatment protocols, and potential barriers and facilitators to randomised controlled trials evaluating these treatments. Results: Both healthcare professionals and patients were supportive of the proposed trials. Key findings included that healthcare professionals recommended clarity on patient eligibility, hospitalisation criteria and consent procedures. Patients expressed a desire to be given more detailed information about potential trials and had mixed opinions on self-monitoring. There were some concerns from both parties about treatment risks, particularly the paracentesis. Healthcare professionals noted a shift to more preventative practice due to the COVID-19 pandemic. Conclusions: Outpatient paracentesis and gonadotropin-releasing hormone antagonists were perceived as promising interventions. Potential concerns and recommendations around both acceptability and feasibility were raised, which were used to refine the treatment protocols for the Shaping and Trialling Outpatient Protocols for Ovarian Hyperstimulation Syndrome trial. Funding: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128137.


  • Open Access

    Removal of small fibroids and polyps in patients with infertility and recurrent miscarriage: The HELP Fertility? RCT

    by Mostafa Metwally, Kirsty McKendrick, Katie Ridsdale, Clare Pye, Stephen Walters, Saad Amer, Amy Barr, Robin Chatters, Ying Cheong, Meenakshi Choudhary, et al.

    Background: Infertility affects one in six of females globally, with uterine submucous fibroids and endometrial polyps being common findings. The effectiveness of surgical removal to improve fertility remains uncertain. The associated surgical risks and costs highlight the need for more robust research in this area. The HELP Fertility? Study aimed to assess the clinical and cost-effectiveness of hysteroscopic removal of endometrial polyps and submucosal fibroids, compared to no removal, in improving fertility outcomes for participants with infertility or recurrent miscarriage while also evaluating participant experience and longer-term effects. The trial was designed as a multicentre, pragmatic superiority randomised controlled trial with two concurrent trials; one for endometrial polyps and one for submucosal fibroids, with a 9-month feasibility pilot. Participants were randomly assigned 1 : 1 to either receive hysteroscopic resection or no resection. The primary outcome was live birth rate at 15 months. Secondary outcomes included pregnancy rates, procedure details, patient satisfaction and resource use. Results: COVID-19 resulted in significant recruitment challenges, with delays in site set-up and participant enrolment due to pandemic-related healthcare disruptions. The trial was closed early by the National Institute for Health and Care Research–Health Technology Assessment programme following recruitment of 35 participants (19 hysteroscopic resection and 16 no resection) out of a target of 1120. The clinical and cost-effectiveness analyses were severely limited by the small sample size. Clinical pregnancy rates within 15 months of randomisation were 26.5% (5/19) in the hysteroscopic resection group and were 37.5% (6/16) in the no resection group. The live birth rate within 15 months of randomisation (the primary outcome) were 15.8% (3/19) in the hysteroscopic resection group and 18.8% (3/16) in the no resection group: a risk difference of −3.0% (95% confidence intervals −31.1% to 24.2%). No serious adverse events were observed in the follow-up. At the mean, hysteroscopic resection resulted in fewer live births, but increased costs, implying that resection is not cost-effective compared to no resection. However, results were highly uncertain and confidence intervals for incremental costs and the incremental live birth rate spanned zero. At a cost-effectiveness threshold of £20,000 per additional live birth, there is a 10% probability that hysteroscopic resection represents a cost-effective intervention and a 90% probability that no resection is cost-effective. There is a 56% probability that resection is more costly and less effective than no resection. Despite implementing remote training, centralised support and opening 16 National Health Service sites by February 2023, insufficient participants were recruited within planned time frames. The study was ultimately closed as part of the NIHR Research Reset Programme in February 2023. Limitations: With recruitment of 35 participants against a target of 1120 and the follow-up period limited to 15–24 months, the results of this study are limited. Conclusions: The HELP Fertility? Trial faced recruitment challenges, enrolling only 35 participants. Due to the small sample size, researchers could not statistically determine any significant difference in live birth rates between surgical intervention and no resection for small fibroids and polyps. Cost-effectiveness results should be interpreted with caution. Researchers were able to provide valuable insights into clinical research complexities, which include clinician and patient equipoise. Future work: The research highlights several critical considerations for future fertility studies. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128969.


  • Open Access

    Factors associated with oral nutritional behaviours in Neurodegenerative Disorders of the motor system: A systematic review

    by Isobel A Williams, Munira Essat, Dan Beever, Mark Clowes, Elizabeth Coates, Vanessa Halliday, Sean White, David White, Theocharis Stavroulakis, Nicolò Zarotti, et al.

    Background. Excessive weight loss is common in Neurodegenerative Disorders of the motor system (NDMS; e.g., Parkinson’s disease, Amyotrophic Lateral Sclerosis) and is associated with poor health outcomes. Weight loss may arise from disease activity directly (e.g., muscle wastage) and altered oral nutritional behaviours (ONBs). However, little is known about the key factors associated with these oral nutritional behaviours (ONBs) or outcomes.Methods. A systematic search of electronic databases identified papers examining factors (e.g., knowledge, beliefs) associated with ONBs/outcomes (e.g., swallowing, calorie intake, weight) in NDMS. The COM-B model was used to interpret the narrative review and synthesis. Results. Sixty-one quantitative papers and four qualitative papers were included. The most consistent correlates of poorer ONBs/outcomes were disease characteristics including severity, duration, and dysphagia (Capability–Physical). Cognitive impairment and lack of knowledge about high calorie diets (Capability–Psychological) and the absence of caregivers (Opportunity–Social/Physical) were related to poorer ONBs/outcomes. Patients’ desire for independence was related to better outcomes whereas low perceived need and low response efficacy of a high calorie diet were related to poorer ONBs/outcomes (Motivation–Reflective). Eating habits, depression, and lack of appetite related to poorer outcomes (Motivation–Automatic).Conclusion. Quantitative studies focused on the impact of disease characteristics on nutritional outcomes, whereas qualitative studies explored the impact of NDMS on ONBs in the context of everyday life. Together, these findings highlight that interventions to prevent weight loss in people with NDMS should target their capabilities, opportunities and motivations and be tailored to their disease stage and living circumstances.

  • Open Access

    Acceptance and Commitment Therapy for people living with motor neuron disease: the COMMEND feasibility study and randomised controlled trial

    by Rebecca L Gould, Benjamin J Thompson, Charlotte V Rawlinson, Matt Bursnall, Mike Bradburn, Anju D Keetharuth, Tracey Young, Vanessa Lawrence, David A White, Robert J Howard, et al.

    Background: Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Formal psychological therapies are not routinely part of United Kingdom standard motor neuron disease care due to a lack of evidence-based guidance resulting from a paucity of clinical trials. We aimed to evaluate the clinical and cost-effectiveness of Acceptance and Commitment Therapy plus usual care compared to usual care alone for improving psychological health in people living with motor neuron disease. Methods: We conducted qualitative interviews with 15 people living with motor neuron disease, 10 caregivers and 12 healthcare professionals. Findings were used to develop an Acceptance and Commitment Therapy intervention specifically for people living with motor neuron disease. Next, we examined its acceptability and feasibility in an uncontrolled feasibility study with 29 people living with motor neuron disease. Findings from qualitative interviews with 14 people living with motor neuron disease and 11 therapists were used to revise the intervention. Finally, we conducted a multicentre, parallel, two-arm randomised controlled trial in 16 United Kingdom motor neuron disease care centres/clinics. Eligible participants were aged ≥ 18 years with motor neuron disease. Participants were randomly assigned (1 : 1) to receive up to eight sessions of Acceptance and Commitment Therapy plus usual care or usual care alone and followed up at 6 and 9 months post randomisation by blinded outcome assessors. The primary outcome was total score on the McGill Quality of Life Questionnaire-Revised at 6 months. Secondary outcomes included health status using the EuroQol-5 Dimensions, five-level version. Primary analyses were by intention to treat. Results: Acceptance and Commitment Therapy was acceptable to people living with motor neuron disease, and it was feasible to recruit participants, hence trial progression criteria were met. From September 2019 to August 2022, 191 participants were recruited: 97 were allocated to Acceptance and Commitment Therapy plus usual care and 94 to usual care alone. Mean age was 61.9 years (standard deviation 11.4), 58% were male and 95% were White/White British. Acceptance and Commitment Therapy plus usual care was superior to usual care alone on the McGill Quality of Life Questionnaire-Revised at 6 months [adjusted mean difference 0.66 (95% confidence interval 0.22 to 1.10); Cohen’s d = 0.46 (95% confidence interval 0.16 to 0.77); p = 0.003] and 9 months [adjusted mean difference 0.76 (95% confidence interval 0.30 to 1.22); Cohen’s d = 0.53 (95% confidence interval 0.21 to 0.85); p = 0.001]. Mean differences in total costs and quality-adjusted life-years at 9 months between Acceptance and Commitment Therapy plus usual care versus usual care alone were not statistically significant [costs: £1019 (95% confidence interval −£34 to £2074); quality-adjusted life-years: 0.019 (95% confidence interval −0.07 to 0.05)]. The incremental cost-effectiveness ratio was £88,507/quality-adjusted life-year: this decreased to £13,817/quality-adjusted life-year in those with medium disease-related deterioration in subgroup analyses. Conclusion: Acceptance and Commitment Therapy plus usual care is clinically effective at maintaining or improving psychological health, as measured by the McGill Quality of Life Questionnaire-Revised, in people living with motor neuron disease compared to usual care alone. It was not cost-effective overall when calculated using a standard health status measure (EuroQol-5 Dimensions, five-level version). However, it was cost-effective in a subgroup of people experiencing a medium rate of disease-related deterioration. Limitations: Participants from ethnic minorities were under-represented, despite recruiting from sites with diverse communities. Between-group differences in outcomes may have been partly attributable to expectancy or non-specific therapeutic effects due to the lack of an active control. Cost-effectiveness analyses may have been underpowered to detect significant between-group differences. Future work: Studies should examine the effectiveness of Acceptance and Commitment Therapy in diverse populations, compared to an active control, using a more appropriate measure to assess cost-effectiveness, and in those with different rates of disease-related deterioration. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16/81/01.


  • Open Access

    Optimising Calorie Intake for People With Amyotrophic Lateral Sclerosis: A Process Evaluation of a Complex Behaviour Change Intervention

    by Katie Hullock, Alicia O'CAthain, Fiona Sampson, Jonathan Woodward, Elizabeth Coates, Theocharis Stavroulakis, Sean M. White, David White, Paul Norman, Christopher McDermott

    Objective: To explore intervention fidelity and experiences of using a new intervention designed to optimise calorie intake in people with amyotrophic lateral sclerosis (ALS). Methods: A mixed‐methods process evaluation was conducted alongside an ongoing randomised controlled trial across 15 ALS specialist centres in the United Kingdom. Data collection included 146 healthcare professional‐completed fidelity checklists, audio recordings of 5 intervention sessions, and qualitative interviews with 32 healthcare professionals, patients and informal caregivers. Results: Intervention fidelity was high (88%: 1059/1204 items completed by healthcare professionals). Healthcare professionals, patients and informal caregivers within the sample recognised the intervention's value and engaged with it. Patients were motivated to use the intervention because they believed it could slow disease progression, and it gave them a sense of control. Despite challenges with the intervention, including patient concerns about weight gain and physical limitations in food preparation and consumption, patients in this sample remained committed to using the intervention. However, healthcare professionals suggested that these challenges may have negatively influenced trial recruitment and retention. Caregivers played a crucial role in supporting patients emotionally and physically, helping them to adhere to the intervention. Conclusions: The intervention was feasible to implement and was delivered with fidelity. While patient engagement in this sample was strong, the intervention usability may be time‐limited as physical function declines. Therefore, the intervention may be best suited for those with slower‐progressing ALS who can manage the intervention and dietary changes. Moving forward, continued evaluation is needed to assess effectiveness and explore subgroup differences based on ALS type (slow vs. fast progressing). PPIE Contribution: PPI was integral to the process evaluation. PPI members reviewed key study documents, including the Participant Information Sheet and consent forms, leading to participant materials that were clear and easily understood. They also participated in developing the intervention. Trial Registration: IRAS ID 275949, ISRCTN30588041.


  • Open Access

    Ovarian Hyperstimulation Syndrome: The STOP-OHSS RCT of outpatient paracentesis and survey on preventive practices

    by Mostafa Metwally, Katie Ridsdale, Munya Dimairo, Clare Pye, Ying Cheong, Lauren Desoysa, Andrew Drakely, Isaac Evbuomwan, Jane Hughes, Amanda Loban, et al.

    Introduction Ovarian Hyperstimulation Syndrome (OHSS) is a potentially serious complication of ovarian stimulation and Assisted Reproductive Technologies. This study aimed to assess the effectiveness of early outpatient paracentesis in preventing symptom progression and hospitalisation of OHSS patients, and resulting in earlier resolution of the condition. Methods A randomised controlled trial was conducted, randomly allocating fertility centre patients with moderate or severe OHSS to either conservative management (n = 5), or outpatient paracentesis with increased monitoring (n = 3). Randomisation was computer-generated, and the primary outcome was OHSS-related hospitalisation. Due to recruitment challenges, particularly pertaining to the SARS-CoV-2 (COVID-19) pandemic, the trial was closed early after randomising eight participants from three sites. A post-trial survey was conducted to examine changes in clinical practices at UK fertility centres during and after the COVID-19 pandemic. Results Of the eight participants, two were hospitalised for OHSS-related reasons. Six participants’ symptoms resolved during follow-up, while two had unknown outcomes. No significant adverse events related to paracentesis were reported. The post-trial survey, completed by 16 fertility centres, revealed that 31% of respondents believed OHSS incidence had decreased during and after COVID-19. Many centres reported increased use of preventive strategies during and after COVID-19. For example, 91% of sites reported that they increased their elective freeze rates; 53% increased their use of the antagonist protocol; and 53% increased their use of Gonadotropin-Releasing Hormone (GnRH) trigger for final oocyte maturation. Conclusions The small sample size precludes definitive conclusions, however, outpatient paracentesis appears to be a safe option for managing OHSS. The study highlights challenges in researching rare conditions with rapid disease progression. The survey demonstrated that these challenges may also be reflective of radical changes in practice during the pandemic, which may have decreased the risk of OHSS significantly. The trial registration number was ISRCTN71978064, and the project was funded by the National Institute for Health and Care Research Health Technology Assessment programme (NIHR128137).

  • Open Access

    Randomised controlled trial with parallel process evaluation and health economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with amyotrophic lateral sclerosis: study protocol

    by Arron Peace, David Alexander White, Gemma Hackney, Mike Bradburn, Paul Norman, Sean White, Ammar Al-Chalabi, Wendy Baird, Daniel Beever, Janet Cade, et al.

    Introduction Amyotrophic lateral sclerosis (ALS) is a devastating illness that leads to muscle weakness and death usually within around 3 years of diagnosis. People with ALS (pwALS) often lose weight due to raised energy requirements and symptoms of the disease presenting significant challenges to taking adequate oral diet, with those who lose more weight being at a greater chance of earlier death. There is also some evidence to suggest that a higher calorie diet may benefit the disease course in pwALS, but further research is needed. Methods and analysis Two armed, parallel group, superiority, open labelled, randomised controlled trial, with internal pilot, to assess the effectiveness of an early high calorie diet on functional outcomes in ALS, comprising two treatment arms: (1) standard care, (2) standard care with additional active management using the OptiCALS complex intervention to achieve a high calorie diet (initially randomised 1:1, then 1:2 following a protocol amendment). Using a food first approach, pwALS will be encouraged and supported to follow a diet that meets an individualised calorie target from food before prescribing oral nutritional supplements. 259 pwALS will be recruited from up to 20 ALS centres across the United Kingdom and Ireland and followed up for a period of 12 months. Primary outcome is functional change measured over 12 months, using the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale. Secondary end points include measures of functional health, quality of life, calorie intake and weight, as well as time to gastrostomy and survival. A health economic analysis and process evaluation will also be undertaken. Participant recruitment is expected to complete in September 2025, and participant follow-up is expected to complete in September 2026. The results of this study are expected in March 2027. Ethics and dissemination The trial was approved by Greater Manchester—North West Research Ethics Committee, reference 20/NW/0334 on 8 September 2020. We will publish the study findings in peer-reviewed academic journals and present at local, national and international conferences where possible. Trial registration number ISRCTN30588041.


  • Open Access

    Multiple Symptoms Study 3 – An extended-role general practitioner clinic for patients with persistent physical symptoms: a Randomised Controlled Trial

    by Christopher Burton, Cara Mooney, Laura Sutton, David White, Jeremy Dawson, Kate Fryer, Monica Greco, Michelle Horspool, Aileen Neilson, Gillian Rowlands, et al.

    Background: People with multiple and persistent physical symptoms have impaired quality of life and poor experiences of health care. We aimed to evaluate the effectiveness of a community-based Symptoms Clinic intervention in people with multiple and persistent physical symptoms. Trial design: Pragmatic multicentre individually randomised parallel group clinical trial. Methods: Participants: Recruitment was between December 2018 and December 2021 in four areas of the UK. Eligibility was based on electronic health records, healthcare use and multiple physical symptoms (PHQ-15 between 10 and 20) which were not due to other medical conditions. Intervention delivery changed from face to face to online in 2020 in response to the pandemic. Interventions: Participants were randomised to receive the Symptoms Clinic plus usual care (intervention) or usual care alone (control). The Symptoms Clinic is a short-term extended medical consultation-based intervention delivered over approximately 8 weeks. Objective: To test the clinical and cost-effectiveness of an extended-role general practitioner ‘Symptoms Clinic’ for people with persistent physical symptoms. Outcome: The primary outcome measure was the PHQ-15 at 52 weeks post randomisation. Randomisation: Participants were randomised 1 : 1 using a centralised web-based system, stratified by study centre with random permuted blocks of varying sizes. Masking: It was not possible to mask participants to their allocation. Outcome assessors who handled patient-reported questionnaires were masked to allocation. Results: Numbers randomised: 354 participants were randomised into the trial: 176 to the usual care group and 178 to the intervention group. Numbers analysed: 132 participants in the usual care group and 144 participants in the intervention group were included in the analysis representing 77.8% retention. Outcome: Mean (SD) PHQ-15 at baseline was 14.9 (3.0) in the control group and 15.0 (2.9) in the intervention group. At 52 weeks it was 14.1 (3.7) in the control group and 12.2 (4.5) in the intervention group. The between-group difference, adjusted for age, sex, baseline PHQ-15 and clinician effect was −1.82 (95% CI −2.67 to −0.97; p < 0.001) favouring the intervention. Harms: There were no significant between-group differences in the proportions of patients experiencing non-serious (−0.03, 95% CI −0.11 to 0.05) or serious (0.02, 95% CI −0.02 to 0.07) adverse events. All serious adverse events were deemed unrelated to trial interventions. Economic evaluation: Cost-effectiveness analysis indicated an incremental cost-effectiveness ratio of £15,751/QALY. Process evaluation: The intervention was delivered with high fidelity and was acceptable to patients. The intervention appeared to act through the hypothesised mechanism of explanation as a bridge from uncertainty about the cause to actions to manage symptoms. Limitations and further research: The intervention was delivered by a small number of GPs in long consultations. Further research should examine wider implementation and how to integrate elements of the intervention into shorter consultations. Conclusions: The Symptoms Clinic delivered by specially trained GPs leads to a clinically meaningful improvement in physical symptoms at 52 weeks and is likely to be a cost-effective addition to current care. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme as award number 15/136/07.

  • Open Access

    Cost-effectiveness of an extended-role general practitioner clinic for persistent physical symptoms: results from the Multiple Symptoms Study 3 pragmatic randomized controlled trial

    by Christopher Burton, Cara Mooney, Laura Sutton, David White, Jeremy Dawson, Kate Fryer, Monica Greco, Michelle Horspool, Aileen Neilson, Gillian Rowlands, et al.

    This article consists of a citation of a published article describing research funded by the Health and Social Care Delivery Research programme under project number 15/136/07, and is provided as as part of the complete record of research outputs for this project. The original publication is available at: https://doi.org/10.1016/j.jval.2024.09.015 Funding: This publication was funded by the Health and Social Care Delivery Research programme as a part of award number 15/136/07. This article reports on one component of the research award Multiple Symptoms Study 3: pragmatic trial of a community based clinic for patients with persistent (medically unexplained) physical symptoms. For more information about this research please view the award page [https://fundingawards.nihr.ac.uk/award/15/136/07] DOI: https://doi.org/10.1016/j.jval.2024.09.015